Cilta-cel vs Standard of Care Therapy for Patients With Lenalidomide-Refractory Multiple Myeloma from binod Watch Video
Preview(s): Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Your browser does not support playing the video.Please download the video!
Description: At the 2023 ASCO Annual Meeting, Binod Dhakal, MD, presented phase 3 results from CARTITUDE-4 on the use of ciltacabtagene autoleucel therapy versus the standard of care therapy for patients with lenalidomide-refractory multiple myeloma.